Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus SYNJARDY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus SYNJARDY XR.
CYCLOSET vs SYNJARDY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Synjardy XR is a combination of empagliflozin, an SGLT2 inhibitor that reduces renal glucose reabsorption, and metformin, an AMPK activator that decreases hepatic glucose production and improves insulin sensitivity.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Initial dose: 5 mg empagliflozin/500 mg metformin extended-release orally twice daily with meals. Titrate based on glycemic control and tolerability up to maximum 25 mg empagliflozin/1000 mg metformin XR twice daily.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Empagliflozin: Terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: Terminal half-life ~6.2 hours (plasma); elimination half-life prolonged in renal impairment (up to 17.6 hours in patients with reduced GFR).
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Empagliflozin: Approximately 54% excreted unchanged in urine, 41% in feces (metabolites). Metformin: ~90% excreted unchanged in urine via tubular secretion and glomerular filtration; renal clearance ~510 mL/min.
Category C
Category C
Dopamine Agonist / Antidiabetic
Antidiabetic